These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Levine MJ Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042 [TBL] [Abstract][Full Text] [Related]
8. Effects of SGLT2 inhibitors on cardiovascular outcomes. Foote C; Perkovic V; Neal B Diab Vasc Dis Res; 2012 Apr; 9(2):117-23. PubMed ID: 22381403 [TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903 [TBL] [Abstract][Full Text] [Related]
10. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Abdul-Ghani MA; Norton L; DeFronzo RA Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881 [TBL] [Abstract][Full Text] [Related]
11. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Riggs K; Ali H; Taegtmeyer H; Gutierrez AD Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313 [TBL] [Abstract][Full Text] [Related]
12. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus. Dailey GE Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032 [TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Raskin P Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735 [TBL] [Abstract][Full Text] [Related]
15. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs. Chrysant SG Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076 [TBL] [Abstract][Full Text] [Related]
16. Adverse effects and safety of SGLT-2 inhibitors. Halimi S; Vergès B Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069 [TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors and renal function. Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782 [No Abstract] [Full Text] [Related]
18. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. Mazidi M; Rezaie P; Gao HK; Kengne AP J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454 [TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Gurgle HE; White K; McAdam-Marx C Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752 [TBL] [Abstract][Full Text] [Related]
20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]